CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30‐POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202). (12th June 2019) - Sawas, A.